MedPath

MEDIWOUND LTD

MEDIWOUND LTD logo
🇮🇱Israel
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

24

Active:8
Completed:9

Trial Phases

3 Phases

Phase 1:6
Phase 2:6
Phase 3:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (33.3%)
Phase 2
6 (33.3%)
Phase 3
6 (33.3%)

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

Phase 2
Not yet recruiting
Conditions
Venus Leg Ulcers
Interventions
Drug: EscharEx (EX-03)
Drug: Placebo (Gel vehicle)
First Posted Date
2024-11-15
Last Posted Date
2024-11-15
Lead Sponsor
MediWound Ltd
Target Recruit Count
45
Registration Number
NCT06690177
Locations
🇺🇸

ILD Research Center, Carlsbad, California, United States

🇵🇱

Wojskowy Instytut Medyczny, Warsaw, Poland

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

Phase 3
Recruiting
Conditions
Venous Leg Ulcer (VLU)
Interventions
Drug: EscharEx (EX-03)
Drug: Placebo (Gel vehicle)
First Posted Date
2024-08-23
Last Posted Date
2025-04-24
Lead Sponsor
MediWound Ltd
Target Recruit Count
216
Registration Number
NCT06568627
Locations
🇺🇸

Limb Preservation Platform, Inc, Fresno, California, United States

🇺🇸

Center for Clinical Research INC, San Francisco, California, United States

🇺🇸

Northwell Health Comprehensive Wound Healing Center, Lake Success, New York, United States

and more 2 locations

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Phase 1
Conditions
Nodular Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Interventions
Drug: EscharEx 5% (EX-02 formulation)
First Posted Date
2021-12-15
Last Posted Date
2021-12-15
Lead Sponsor
MediWound Ltd
Target Recruit Count
32
Registration Number
NCT05157763
Locations
🇺🇸

Center for Clinical and Cosmetic Research, Aventura, Florida, United States

🇺🇸

Moore Clinical Research, Inc., Brandon, Florida, United States

🇺🇸

Center for Clinical Studies, LTD. LLP, Webster, Texas, United States

A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

Phase 2
Completed
Conditions
Venous Leg Ulcer
Diabetic Foot Ulcer
Interventions
Drug: EscharEx (EX-02 formulation)
First Posted Date
2021-03-26
Last Posted Date
2022-07-26
Lead Sponsor
MediWound Ltd
Target Recruit Count
12
Registration Number
NCT04817228
Locations
🇺🇸

Barry University foot and ankle institute, Tamarac, Florida, United States

🇺🇸

Clinical Research Medical Center, LLC, Las Vegas, Nevada, United States

🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Conditions
Thermal Burn
First Posted Date
2019-08-01
Last Posted Date
2024-08-30
Lead Sponsor
MediWound Ltd
Registration Number
NCT04040660
Locations
🇺🇸

University of South Alabama, Mobile, Alabama, United States

🇺🇸

Valleywise Health Medical Center, Phoenix, Arizona, United States

🇺🇸

University of California, Irvine, Orange, California, United States

and more 25 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.